Skip to content

Impact of COPD on Muscle Regeneration

Impact of Chronic Obstructive Pulmonary Disease on Peripheral and Respiratory Muscle Regeneration

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02557165
Enrollment
27
Registered
2015-09-23
Start date
2011-01-31
Completion date
2015-12-31
Last updated
2015-09-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COPD

Keywords

Muscle regeneration

Brief summary

Muscle weakness and atrophy are important consequences of chronic obstructive pulmonary disease (COPD) and can affect both respiratory and peripheral muscles. Impaired muscle regeneration is thought to be implicated in the process of muscle atrophy. In this study the investigators will evaluate muscle regenerative potential of the Vastus Lateralis (VL) and diaphragm of patients with COPD, compared to patients with normal lung function.

Detailed description

Preliminary results suggest that the activation and differentiation processes of satellite cells isolated from the VL of patients with COPD could be altered. The investigators propose to compare the regenerative potential of the VL and the diaphragm in 15 patients with COPD and 15 individuals with normal lung function undergoing a thoracic surgery. From muscle biopsies, satellite cells will be isolated and cultured to assess their proliferation and differentiation rates, and the expression level of myogenic effectors (MyoD, Myf5, myogenin, and MRF4). Alterations in these measurements will confirm the hypotheses that the regenerative potential is lower in both muscle groups in patients with COPD compared to controls and that in COPD, the regenerative potential is lower in VL compared to the diaphragm.

Interventions

Muscle biopsies will allow acces to samples for observational studies. Vastus latetalis: needle biopsy (Bergstrom technique). Diaphragm: open biopsy performed by thoracic surgeon during lung surgery.

Sponsors

GlaxoSmithKline
CollaboratorINDUSTRY
Laval University
Lead SponsorOTHER

Study design

Observational model
CASE_CROSSOVER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
40 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Patient with a scheduled thoracic surgery * ≥ 40 years * Smoking cessation ≥ 1 month * Smoking history ≥ 10 pack-year

Exclusion criteria

* Subjects who received either chemiotherapy or radiotherapy * Hypoxemia * Body weight loss ≥ 10% * Use of systemic corticosteroid in the last month

Design outcomes

Primary

MeasureTime frameDescription
Muscle satellite cell proliferation indexSequential analyses performed over a period of 2 weeks after tissue collection.Isolation from muscle biopsies of satellite cell to evaluate their regeneration capacity by evaluating the proliferation capacity
Muscle satellite cell differentiation indexSequential analyses performed over a period of 2 months after tissue collection.Isolation from muscle biopsies of satellite cell to evaluate their regeneration capacity by evaluating the differentiation capacity

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026